SINGULUS

REPORT FOR THE THIRD QUARTER 2021

Interim Report as of September 30, 2021 (unaudited)

Innovations for New Technologies

Report for the Third Quarter 2020 (preliminary, unaudited)

SINGULUS TECHNOLOGIES presents a vacuum deposition system for semiconductor technology at CIIE 2021, Shanghai, China.



On November 7, 2021 SINGULUS TECHNOLOGIES has agreed on a cooperation with Konka Group, China, (Konka). At CIIE 2021 in Shanghai, Dr. Stefan Rinck, CEO SINGULUS TECHNOLOGIES, signed a corresponding cooperation agreement with Konka for the development and delivery of vacuum deposition systems for the production of micro LEDs.

Table of Content

Business Trends and Situation of the SINGULUS TECHNOLOGIES Group

- → *New orders for the delivery of production machines for thin-film solar modules (CdTe and CIGS)*
- → *Significant sales and earnings increases*
- → *Key orders in the segments Life Science and Semiconductor*
- → *Order backlog at € 105.6 million as of September 30, 2021*
- → *Gross margin develops positively at 29.2 percent*
- → *Audit certificate for the 2020 annual financial statements still outstanding*

In the first nine months SINGULUS TECHNOLOGIES was able to increase sales from € 21.9 million in the prior-year period to € 45.5 million this year. Sales in the third quarter came to € 19.5 million (previous year: € 5.7 million). The operating earnings before interest and taxes (EBIT) for the first nine improved and came to € -7.6 million (previous year: € -20.6 million). In the third quarter a positive EBIT in the amount of € 0.3 million (previous year: € -6.3 million) was achieved. During the first nine months of the business year 2021 the order intake came to € 73.3 million, above the prior-year level of € 70.9 million in 2020. As of September 30, 2021, the order backlog was also increased compared with the previous year and currently amounts to € 105.6 million (previous year: € 75.3 million). With the receipt of the orders during the reporting period the order backlog will continue to increase. The unrestricted, available liquidity of SINGULUS TECHNOLOGIES amounted to € 13.3 million as of September 30, 2021 compared with € 9.8 million as of December 31, 2020. During the reporting period for 2021, the gross profit margin developed considerably favorably due to the higher utilization level as well as the changed product mix within the production and amounted to 29.2 % (previous year: -0.9 %).

After the completion of the reporting period, additional significant orders were received in October. Here, the signing of contracts for machines for the production of thin-film solar modules with China Triumph International Engineering Co. Ltd. (CTIEC), Shanghai, China, a subsidiary of the China National Building Materials Group (CNBM), Beijing, China, stands out. The concluded order includes the delivery of production machines for manufacturing sites for the production of both CdTe and CIGS thin-film solar modules through sputtering, vaporization and sublimation. The total order value amounts to approximately € 25 million. On the basis of the contractual agreements, the planned prepayments are expected to be received in the course of November 2021. Besides additional measures to improve the financing structure, these significant contracts are a prerequisite for the attestation of the positive going-concern assumption by the appointed auditors. This going-concern assumption is a prerequisite for the receipt of the still pending attestation for the financial statements 2020. In addition to the cash-flows from the operating activities, the company is mainly financed through a corporate bond with a nominal value of € 12.0 million as well as a senior-secured loan in the amount of € 4.0 million. At present, the company's through-financing is not sufficiently guaranteed for the required period of 24 months, which is why the auditor's certificate for the 2020 financial year is still pending.

The headcount within the SINGULUS TECHNOLOGIES Group decreased slightly to 338 employees as of September 30, 2021 (December 31, 2020: 349 employees).

Solar Segment

In its "Net Zero 2050" plan for the "COP 26" UN Climate Change Conference the International Energy Agency (IEA) describes how net emissions can be reduced to zero globally by 2050. For this, from 2030 each year more than 1000 gigawatt wind power and photovoltaic plants have to be added globally. Thereof, 630 gigawatt is attributable to solar power, which means a five-folding of capacity compared with 2020. In China alone, additional 100 GW capacity for wind and solar should be installed to offset the bottlenecks of the energy supply in the short-term. Accordingly, China will continue to invest heavily into photovoltaics in the next couple of years.

Solar Power Europe and IHS Markit have also considerably raised their forecasts for photovoltaic additions in the current year – from 158 to 181 GW. It is expected that China will once again be the largest global market in 2021 with around 60 % newly installed photovoltaic output. Solar energy is thus the decisive factor for the setup of a secure and sustainable energy system.

An additional focus of activities in the Solar segment is set on new production sites for high-performance solar cells. There are several initiatives in Europe based on this technology to plan the cell production at a gigawatt scale. In several countries these goals are also supported by financial aid through the Fund for European Aid. SINGULUS TECHNOLOGIES has developed machines for the manufacturing of high-performance solar cells and is engaged in numerous projects. The company's goal is to establish itself as a technologic leader for the key process steps used in the production of highly efficient cells.

In addition to the four already existing CIGS sites, CNBM plans several other production sites for CdTe solar cells with an output volume exceeding one gigawatt. In this year's May CNBM and SINGULUS TECHNOLOGIES agreed on a cooperation project for the development of the next generation vacuum coating machines for the production of CdTe thin-film solar cells. It is SINGULUS TECHNOLOGIES' goal to reduce the production costs with the new machine generation, to improve the efficiency and to increase the output.



Newly-developed GENERIS PECVD system for high-performance solar cells.

It is expected that the production capacities for CIGS and CdTe solar modules will also increase considerably in the coming years. SINGULUS TECHNOLOGIES is in talks with customers for all of the key investments in China with respect to machines for various manufacturing processes for thin-film solar modules. From SINGULUS TECHNOLOGIES' perspective, all of the framework conditions are therefore in favor of long-term growth for the company in the key solar market.

Semiconductor Segment

SINGULUS TECHNOLOGIES delivered the first TIMARIS III this year. This is a new production machine. The new machine design is developed for the traditional 300 mm semiconductor wafer production and has been commissioned by the customer in the meantime.

In October, SINGULUS TECHNOLOGIES received a new order for a vacuum coating machines of the ROTARIS type from a European semiconductor manufacturer. The application area is the mass production of high-precision, magnetic TMR (tunnel magneto resistance) sensors, which conquer more and more applications such as in the segments automotive, photovoltaics converter and manufacturing. The contract volume is in a low single-digit million € range. The cluster tools of the ROTARIS enable the application of reproducible coatings under production conditions with precision of one tenth Angstrom (10^{-11} m) in ultra-high vacuum. This is less than one atomic mono layer applied homogeneously to a wafer with a diameter of 300mm. Amongst others, the areas of application are in the automotive industry, charging infrastructure for electric vehicles and photovoltaic



ROTARIS vacuum deposition system for the serial production of highly precise magnetic TMR sensors.

converters. In addition to its use for the industrial production, the machine is also well suited for research and development application requiring a high degree of flexibility.

Life Science Segment

In this segment the work areas Medical Technology, Decorative Coatings and Data Storage are combined. In the past couple of years, in particular the activities in the divisions Decorative Coatings and Medical Technology were extensively expanded.

For medical technology SINGULUS TECHNOLOGIES offers production machines for wet-chemical processes as well as various methods of vacuum coating technology. Within this application area the company is mainly active in the market for production machines for contact lenses. The processing machine MEDLINE by SINGULUS TECHNOLOGIES cleans contact lenses from residues and subsequently coats the lenses in the course of an additional processing step. With its innovative processes SINGULUS TECHNOLOGIES meets the GMP ("Good Manufacturing Practice") and thus the international rules and regulations. The machines meet the high demands of medical technology. A customer, who is already using several machines of the MEDLINE type in its production, has placed a new order in April 2021 for several production lines for contact lenses. An additional, significant order for the delivery of several new processing machines was recorded in August 2021. The order volume is in a low double-digit € range. In this market, SINGULUS TECHNOLOGIES still expects new order intake before end of the year.

With the vacuum coating machine POLYCOATER as well as with the integrated production line DECOLINE II, SINGULUS TECHNOLOGIES has successfully established production machines, which continue to assert themselves in the market. Several new systems were ordered for the environmentally-friendly surface treatment of 3D-components.



MEDLINE wet processing system for cleaning and coating of contact leses.

Following an order for a DECOLINE II from the US, which was received at the beginning of the year, a European customer operating in the cosmetics sector, who had already ordered a DECOLINE II system in 2019, has further expanded its capacities. It is pleasing to note that this customer has once again opted for the environmentally-friendly and cost-efficient product solution from SINGULUS TECHNOLOGIES.

The overall order includes a complete production line DECOLINE II and in addition the order for two newly-developed coating units for UV coatings under the product name PAINTLINE. The customer is already very successfully operating a DECOLINE II from SINGULUS TECHNOLOGIES, which excels with high quality of the products produced on it as well as an extremely low reject rate. This eliminates high logistics efforts and long transport routes. Furthermore, the components and material inventories in circulation can be reduced and varying end-customer request can be responded to at short notice. Plasma processes are not more expensive than galvanic coating. Systems that work according to the principle of sputtering (Physical Vapor Deposition, PVD) are somewhat more expensive to purchase than a corresponding electroplating system, but in terms of operating costs, capacity and thus unit costs, they have a clear advantage.

In addition to photovoltaics, this is another example of how SINGULUS TECHNOLOGIES is successfully positioned for the future with its environmentally-friendly processes and coating machines.

In the work area optical Data Storage the service and replacement part activities shadows the declining trend of optical storage media. This trend was amplified in the quarter under review mainly due to the shutdown of production capacities resulting from the COVID19 pandemic. New applications in the area of optical data storage technology will remain a niche market in the future.

DECOLINE II for environmentally friendly finishing of plastic and metal surfaces for applications in cosmetics and automotive industry as well as for numerous other consumer goods.



Key financial figures

Order intake and order backlog

The order intake reached € 73.3 million in the period under review. The order intake in the same period 2020 amounted to € 70.9 million. In the third quarter the order intake came to € 37.0 million (previous year: € 4.0 million). The majority hereof is attributable to the unit Medical Technology within the Life Science segment. The order backlog increased to € 105.6 million as of September 30, 2021 (September 30, 2020: € 75.3 million). This amount does not include the delivery contracts for CdTe and CIGS equipment dated October 29, 2021 in the amount of approximately € 25 million. The contracts only become legally effective with the receipt of the first prepayment. The receipt of the first prepayment for the contract for the CIGS equipment depends on the provision of guarantees by the company to customer.

Sales and earnings

The global impacts of the COVID-19 pandemic also burdened the key financial results in the first nine months of 2021. However, sales in the first nine months of the business year 2021 of € 45.5 million were significantly above the prior-year level of € 21.9 million. A further improvement in the utilization is expected for the fourth quarter 2021. Specifically, sales in the first nine months of 2021 are split into € 25.0 million in the Solar segment (previous year: € 8.2 million), Life Science at € 15.4 million (previous year: 11.0 million) and Semiconductor at € 5.1 million (previous year: € 2.7 million). In the third quarter 2021 sales came to € 19.5 million (previous year: € 5.7 million). In the quarter under review sales were split into € 9.5 million in the Solar segment (previous year: € 1.2 million), Life Science at € 9.0 million (previous year: 4.1 million) and Semiconductor at € 1.0 million (previous year: € 0.4 million).

For the first nine months of 2021 the percentage regional breakdown of sales was as follows: Asia 56.9 % (previous year: 31.5 %), Europe 32.1 % (previous year: 47.0 %), North and South America 10.8 % (previous year: 21.0 %) as well as Africa and Australia 0.2 % (previous year: 0.5 %). The percentage regional breakdown of sales for the third quarter 2021 was as follows: Asia 60.1 % (previous year: 21.1 %), Europe 31.2 % (previous year: 56.1 %), North and South America 8.7 % (previous year: 22.8 %) as well as Africa and Australia 0.0 % (previous year: 0.0 %).

In the first nine months of 2021 the gross profit margin developed considerably positively and amounted to 29.2 % (previous year: -0.9 %). The gross profit margin in the third quarter 2021 stood at 31.3 % (previous year: 7.0 %). The main reason for this development was a significant pick-up in business activities and a resulting higher utilization of the production capacities as well as an improved product mix.

The operating expenses in the first nine months of 2021 amounted to € 20.9 million and were below the comparable prior-year level of € 20.4 million. The expenses in the previous year were mainly lower due to short-time labor, the reduction of work-time deposits as well as savings measures in the sales & marketing and administrative functional areas. Specifically, the expenses for research and development amounted to € 5.9 million (previous year: € 6.5 million) below the prior-year level, for sales & marketing and customer services to € 8.2 million (previous year: € 7.5 million) and general & administrative expenses to € 7.0 million (previous year: € 6.6 million) above the prior-year level. The other operating expenses came to € 0.1 million (previous year: € 0.4 million), the other operating income stood at € 0.3 million (previous year: € 0.6 million).

In the quarter under review the expenses for research and development amounted to € 1.5 million (previous year: € 2.0 million), for sales & marketing and customer services to € 2.1 million (previous year: € 2.5 million) and general & administrative expenses to € 2.1 million (previous year: € 2.2 million). The other operating expenses came to € 0.1 million (previous year: € 0.3 million), the other operating income stood at € 0.0 million (previous year: € 0.3 million).

Overall, in the first nine months of 2021 earnings before interest and taxes (EBIT) were negative at € -7.6 million (previous year: € -20.6 million). In the third quarter 2021 the company achieved an EBIT in the amount of € 0.3 million (previous year: € - 6.3 million).

Balance sheet and liquidity

In the period under review the short-term assets totaled € 54.0 million and were thus considerably above the prior-year level (December 31, 2020: € 33.1 million).

	Segment Solar		Segment Life Science		Segment Semiconductor		SINGULUS TECHNOLOGIES Group	
Segment Reporting from January 1 to September 30, 2021 and 2020	**2021 million €**	2020 million €	**2021 million €**	2020 million €	**2021 million €**	2020 million €	**2021 million €**	2020 million €
9-month figures								
Sales (gross)	**25.0**	**8.2**	**15.4**	**11.0**	**5.1**	**2.7**	**45.5**	**21.9**
Sales deduction and individual selling expenses	**0.0**	**0.0**	**-0.1**	**-0.2**	**0.0**	**0.0**	**-0.1**	**-0.2**
Sales (net)	**25.0**	**8.2**	**15.3**	**10.8**	**5.1**	**2.7**	**45.4**	**21.7**
Write-offs and amortization	**-2.2**	**-2.6**	**-0.6**	**-0.8**	**-0.1**	**-0.1**	**-2.9**	**-3.5**
Operating result (EBIT)	**-6.0**	**-14.0**	**-0.5**	**-4.2**	**-1.1**	**-2.4**	**-7.6**	**-20.6**
Financial result							**-0.9**	**-1.6**
Earnings before taxes							**-8.5**	**-22.2**
Third Quarter								
Sales (gross)	**9.5**	**1.2**	**9.0**	**4.1**	**1.0**	**0.4**	**19.5**	**5.7**
Sales deduction and individual selling expenses	**0.0**	**0.0**	**-0.1**	**0.0**	**0.0**	**0.0**	**-0.1**	**0.0**
Sales (net)	**9.5**	**1.2**	**8.9**	**4.1**	**1.0**	**0.4**	**19.4**	**5.7**
Write-offs and amortization	**-0.4**	**-0.9**	**-0.2**	**-0.3**	**0.0**	**0.0**	**-0.6**	**-1.2**
Operating result (EBIT)	**-1.0**	**-4.6**	**1.5**	**-0.7**	**-0.2**	**-1.0**	**0.3**	**-6.3**
Financial result							**0.0**	**-0.5**
Earnings before taxes							**0.3**	**-6.8**

The main reason for this is the increase in restricted funds to € 12.1 million (December 31, 2020: € 4.8 million) as well as the free available funds to € 13.3 million (December 31, 2020: € 9.8 million). The increase in the restricted funds is mainly in connection with the deposit of liquid funds as guarantees for prepayments. Work in progress increased to € 6.1 million (December 31, 2020: € 2.4 million).

The long-term assets amounted to € 22.0 million as of September 30, 2021, below the level of the prior period (December 31, 2020: € 24.7 million). This is mainly due to scheduled depreciation to property, plant and equipment. Specifically, the book value of property, plant & equipment decreased by € 1.7 million and the book value of capitalized development expenses by € 1.0 million.

The short-term debt increased compared with the level at the end of 2020 and amounted to € 84.7 million as of September 30, 2021 (December 31, 2020: € 68.5 million). Specifically, the liabilities from production orders rose by € 22.8 million to € 50.2 million due to the prepayments received in connection with large-scale projects in the Life Science segment (December 31, 2020: € 27.4 million). In contrast, following the resolution of the bondholders' meeting on May 6, 2021 to extend the maturity by five years, the corporate bond is now once again reported under long-term liabilities.

The long-term liabilities amounted to € 34.0 million as of September 30, 2021, above the level of the prior period (December, 31, 2020: € 23.7 million). This is mainly due to the extension of the maturity of the corporate bond.

Shareholders' equity

The shareholders' equity within the Group amounts to € -42.7 million as of September 30, 2021 due to the sustained losses, which is fully attributable to the shareholders of the parent company (December 31, 2020: € -34.4 million). However, the company expects its equity position to strengthen significantly in the coming years due to an improving earnings situation.

For the trends in shareholders' equity of the SINGULUS TECHNOLOGIES AG pursuant to HGB please refer to the details presented on page 24 of this report.

Cash flow

In the first nine months of 2021 the operating cash flow in the Group was positive at € 14.4 million (previous year: € 3.6 million). This is mainly due to the receipt of prepayments in connection with customer projects. The cash flow from investing activities came to € -0.5 million (previous year: € -2.6 million). The cash flow from financing activities came to € -10.6 million overall (previous year: € -3.1 million), which is mainly attributable to the provision of guarantees for prepayments.

The maturity of the bond (€ 12.0 million) was extended by five years as per resolution of the bondholders' meeting on May 6, 2021. The entry and thus the effectiveness were completed in July 2021. Overall, the amount of liquid funds increased by € 3.5 million in the first nine months 2021 to currently € 13.3 million (December 31, 2020: € 9.8 million).

Risk Report

SINGULUS TECHNOLOGIES as an internationally operating company continuously monitors the developments in connection with the outbreak of the COVID19 pandemic and its economic consequences for the company. At this point in time due to the emergence of virus variants there is still material uncertainty with respect to the future development of the pandemic. A final assessment of the further impacts on the business operations is thus still not possible. Management is closely monitoring the situation in order to be able to implement required countermeasures.

Within the current risk reporting, the project and the sales market risk for the segments Solar and Life Science as well as the liquidity risk were defined as material risks for the Group.

Sales market risk

In connection with the COVID-19 pandemic the sales targets in the past months, in particular in the first half of 2021, were significantly missed due to project delays. Even against the background of the pick-up in the business activities during the reporting period, the company still assesses the probability of occurrence as high (previous year: high). Even after the signing of delivery contracts with CNBM at the beginning of the business year 2020 for the production site in Xuzhou and the signing of contract for the delivery of CdTe and CIGS equipment totaling approximately € 25 million, the company currently rates the probability of occurrence of the sales market risk as company threatening. In this connection, the company points out that the legal effectiveness of the contracts only materializes upon the receipt of the first prepayment. The receipt of the first prepayment for the contract for the CIGS equipment depends on the provision of guarantees by the company to customer.

The sales market risk in the Solar segment is still rated with an unchanged relevance score of 5 (previous year: 5). Management expects sustained high sales in the solar segment in the next couple of years. Despite the entry into new business areas, this business segment will continue to provide the largest share of sales and earnings contributions in the current business year.

Besides the core segment Solar, the segment Life Science is gaining increasing importance for the further course of business in the next couple of years. The company expects a significant expansion of the business operations within this segment.

Due to the increasing importance of the Life Science segment for the key financial results for the company, the sales market risk for this business segment is rated with a relevance score of 5 (previous year: 5) as well as with a high probability of occurrence (previous year: high). If the anticipated order intake in this segment will fall significantly short of expectations in the current business year and the company will not be successful in winning equivalent alternative projects, this would threaten the continuation of the company.

Liquidity risk

The continuation of the company is essentially depending on the realization of the key earnings and liquidity results as planned in the next two business years. Accordingly, a receipt of partial payments from contracted as well as expected major orders in the future as planned is an essential prerequisite for the continuation of the company. Thereceipt of additional partial payments by the customer CNBM as planned is required, especially the contractually-agreed receipt of prepayments for the delivery contracts signed on 29 October 2021.

There are liabilities from the issuance of a senior-secured loan in the amount of € 4.0 million. The redemption was originally March 1, 2021. The company is currently negotiating an extension of the maturity.

In addition, to further strengthen the liquidity, the company is currently negotiating with support from the Chinese main shareholder CNBM with Chinese commercial banks about the provision of an additional working capital line of credit in the amount of up to € 10.0 million. Depending on the further course of business the use of a credit line to safeguard the financing could become necessary. The Executive Board expects a favorable conclusion of the talks in the course of the fourth quarter 2021.

For the purpose of cash deposits of sureties, at least the temporary release of liquidity that has been blocked to secure the senior secured loan and the bond may be required by the authorized security trustee. Not least because of the conditional release obligations of the security trustee, the company expects to be able to use this liquidity if necessary.

Currently, we still rate the liquidity risk unchanged with a relevance score of 5 (previous year: 5). Despite the receipt of additional partial payments of the customer CNBM during the period under review, we rate the probability of occurrence as being high (previous year: high). In particular, the timely receipt of contractually agreed payments by the customer CNBM as well as the assignment of additional large projects are required. Material payment delays or non-payments could not be compensated for.

The extension of the term of the senior secured loan in the amount of € 4.0 million and, depending on the further course of business, the conclusion of a working capital credit line in the amount of € 10.0 million are elementary components of the going concern. If these loans are not or no longer made available to the Company, the continuation of the Company as a going concern would no longer be adequately ensured.

The aforementioned events and conditions indicate the existence of substantial uncertainty, which can cast significant doubt on the company's ability to continue its business operations and which pose an existence-threatening risk. However, from today's point of view, the company has sufficient freely available liquid funds to safeguard the business operations.

Project risk

If risks materialize in connection with the order processing, they could have a material adverse impact on the business activities in particular in connection with the implementation of larger projects. In particular, the risk of missing the project schedule or project expenses as well as failing to meet the acceptance criteria is viewed as being material. In particular, the work as planned for the delivery of machines for the production of thin-film solar modules for the large customer CNBM is of great importance for the continuation of the company.

Negative implications on the course of the projects could also result in connection with the COVID-19 pandemic. If measures to contain the virus are maintained over a prolonged period of time or expanded, this could lead to substantial delays in the completion of the projects. This could predominantly concern the company's main sales market, China.

In summary, we assess the project risks unchanged with the relevance score of 5 (previous year: 5). The probability of occurrence is assessed as medium, unchanged to the previous year. Generally, we point out that the realization of project risks within major projects would have material negative impacts on the asset, financial and earnings situation of the company. If the projects fail as a whole or in parts or the planned economic success is not sufficiently realized, this could have material negative impacts up to threatening the existence of the company.

Development of costs and prices

From our point of view, the selling prices developed as planned during the period under review. The procurement prices and consequently the material expenses developed within the range of our expectations, but the company has experienced trends towards increasing procurement prices in the past couple of months. Generally, the future development of procurements prices and the realizable selling prices are currently difficult to forecast. The company filed for short-time work from April 1, 2020 to reduce the personnel expenses during the low utilization due to the COVID19 pandemic. In addition, the non-personnel expenses were also reduced.

Research and development

At € 7.2 million the expenses for developments in the first nine months of 2021 were below the prior-year level of € 8.1 million. The expenses for development activities came to € 2.2 million (previous year: € 2.5 million) in the quarter under review.

Headcount

The headcount within the SINGULUS TECHNOLOGIES Group of 338 employees as of September 30, 2021 was below the level of the end of the previous business year (December 31, 2020: 349).

The SINGULUS TECHNOLOGIES stock

SINGULUS TECHNOLOGIES had invited its shareholders to an extraordinary shareholders' meeting on October 29, 2021. Against the background of the spread of the SARS-COV-2 virus only a virtual event without physical presence of the shareholders was planned. In the course of this extraordinary general meeting under agenda item 1 the Executive Board reported on the loss of more than 50 % of the nominal capital pursuant to Art. 92 Para. 1 AktG and informed about the Board's plans and expectations in this context.

Shortly before the commencement of the extraordinary general meeting the company announced the conclusion of contracts with a volume of approx. € 25 million for the delivery of production machines for the manufacturing of CdTe and CIGS solar modules. The contracts for the delivery of the machines were signed in Shanghai, China, on October 29, 2021. This has strengthened the company's financing situation to such an extent that the far-reaching and drastic capital measures proposed for the resolution of the extraordinary general meeting no longer became necessary in this form. Agenda items 2, 3 and 4 were therefore no longer put to the vote by the administration. A capital increase remains a financing option for the future.

At the end of the reporting period the share price of the SINGULUS TECHNOLOGIES stock traded at € 3.60 and rose to € 4.09 due to the positive news. At the print deadline the share price stood at € 5.08.

The freefloat of the SINGULUS TECHNOLOGIES shares currently amount to around 66 %.

SINGULUS TECHNOLOGIES bond

At the end of March 2021, SINGULUS TECHNOLOGIES invited the bondholders to cast their votes in the course of a ballot without presence within a period of time from Wednesday, April 7, 2021 until Friday, April 9, 2021. The vote without a meeting in presence pursuant to Art. 18 and Art 5 seq. SchVG was not quorate since the required quorum of 50% of the outstanding notes (Art. 15 Para. 3 Sent. 1 SchVG) was not achieved. On May 6, 2021, the second bondholders' meeting with regards to the SINGULUS bond was quorate with a quorum of around 34.4 % and approved the proposed resolutions for the extension of the corporate bond with 98.9 %. After the proper filing of all documents, the responsible Clearstream Bank AG, Frankfurt/Main, informed the company that the new terms of the bond have been amended within the global certificate in the meantime. Therefore, the extension of the maturity of the bond by five years to July 22, 2026 as well as the reduction of the interest rate to 4.5 % in the future have become effective.

The specific amended terms of the bond are summarized as follows:

1. *Extension of term to maturity*
   The term to maturity shall be extended by five years from July 22, 2021 to July 22, 2026. Accordingly, the scheduled redemption of the bond shall take place on July 22, 2026.

2. *Adjustment of the interest rate*
   The bond shall offer an interest rate of 4.5 % p.a. from July 22, 2021. The semi-annual payment of interest shall be maintained.

3. *Increase of the redemption amount*
   The redemption amount per corporate bond with a nominal amount of EUR 100.00 shall be increased by € 5.00 to € 105.00. This increase shall also apply in cases of an early redemption of the bond and termination of the bond by the bondholders.

The Company had continued to invite bondholders in September 2021 to vote in a poll without a meeting within the period from October 04 to 06, 2021. The background to this was preparatory decisions for the capital measures planned at the Extraordinary General Meeting on October 29, 2021.

The additional bondholders' meeting for the SINGULUS bond scheduled for October 28, 2021 was postponed on October 27, 2021 by the company and Dr. Olaf Gerber in his capacity as convener and voting chairman of the voting conducted between October 4 and 6, 2021 without meeting. The ongoing, concurrent negotiations about contracts with a considerable order volume were the reason for the postponement of the second bondholders' meeting. The SINGULUS TECHNOLOGIES AG would like to provide the bondholders' of the SINGULUS bond the opportunity to make their decisions based on the most current and complete information and therefore opted for postponing the bondholders' meeting. The Company does not currently plan to invite the bondholders to vote again on the original issue of the amendment to the terms and conditions of the bond.

As of the print deadline, the price of the bond stood at 80.10 % on November 10, 2021.

Outlook

As an internationally operating company SINGULUS TECHNOLOGIES is monitoring the current developments in connection with the COVID-19 pandemic in the business year 2021 as well. The Executive Board of SINGULUS TECHNOLOGIES expects that the impacts of the COVID-19 pandemic will continue to have an impact on the company. However, in the past couple of months the company experienced a significant recovery of the business activities with a resulting substantial increase in the order intake.

Accordingly, a slightly positive EBIT was already achieved in the third quarter 2021. The Executive Board expects this trend to continue in the fourth quarter 2021. However, due to the high share of customer-specific projects, the key financial indicators such as sales and EBIT are to a large extent dependent on the contractually-agreed receipt of components from our suppliers. Due to the global distortions of the supplier markets, there is currently a lack of visibility with respect to future material receipts and consequently sufficiently precise forecasts for targets cannot be made.

The further economic development of the company materially depends on the global business activities in all segments, the order intake as well as the resulting payments. However, the attestation by the appointed auditor for the consolidated financial statements for the business year 2020 drawn up by SINGULUS TECHNOLOGIES is still pending, because the required going-concern assumption is currently not sufficiently grounded from the auditor's perspective. The going-concern assumption of the company materially depends on the economic development, supported by additional order intake, as well as the sufficient financing for the following two business years.

The provision of an additional, unsecured working capital credit line of up to € 10.0 million is necessary to secure the continued existence of the company. For this purpose, the Company is in contact with Chinese commercial banks with the support of the Chinese main shareholder CNBM. Likewise, a successful refinancing of the outstanding senior secured loan in the amount of € 4.0 million is also to be achieved.

This also includes the successful refinancing of the still outstanding, senior-secured loan in the amount of € 4.0 million.

The Executive Board expects a positive conclusion of the talks with the financing partners in the course of the fourth quarter of 2021. Furthermore, order intake is still required for the next few weeks. The advance payments for the contracts signed on October 29, 2021 must be received as planned.

Further order intake is expected to be received in the next couple of weeks. Upon reaching these goals, the Executive Board expects the receipt of the attestation in the remaining course of the fourth quarter 2021.

Best regards,

The Executive Board

SINGULUS TECHNOLOGIES AG

SINGULUS TECHNOLOGIES Group
Balance Sheet

as of September 30, 2021 and December 31, 2020

ASSETS	Sept. 30, 2021 [million €]	Dec. 31, 2020* [million €]
Cash and cash equivalents	**13.3**	9.8
Restricted cash	**12.1**	4.8
Trade receivables	**3.1**	3.2
Receivables from construction contracts	**2.7**	3.1
Other receivables and other assets	**10.3**	3.8
Total receivables and other assets	**16.1**	10.1
Raw materials, consumables and supplies	**6.4**	6.0
Work in process	**6.1**	2.4
Total inventories	**12.5**	8.4
Total current assets	**54.0**	**33.1**
Property, plant and equipment	**10.3**	12.0
Capitalized development costs	**4.2**	5.2
Goodwill	**6.7**	6.7
Other intangible assets	**0.6**	0.6
Deferred tax assets	**0.2**	0.2
Total non-current assets	**22.0**	**24.7**
Total assets	**76.0**	**57.8**

* preliminary and unaudited

EQUITY AND LIABILITIES	Sept. 30, 2021 [million €]	Dec. 31, 2020* [million €]
Trade payables	**9.7**	6.5
Prepayments received	**5.9**	2.7
Liabilities from construction contracts	**50.2**	27.4
Financing liabilities from the issuance of loans	**4.0**	4.0
Financing liabilities from the issuance of bonds	**0.1**	12.7
Current leasing liabilities	**2.4**	2.4
Other current liabilities	**6.8**	7.1
Provisions for restructuring measures	**0.2**	0.2
Tax provisions	**0.5**	0.5
Other provisions	**4.9**	5.0
Total current liabilities	**84.7**	**68.5**
Financing liabilities from the issuance of bonds	**12.0**	0.0
Non-current leasing liabilities	**3.6**	5.2
Pension provisions	**16.9**	17.0
Deferred tax liabilities	**1.5**	1.5
Total non-current liabilities	**34.0**	**23.7**
Total liabilities	**118.7**	**92.2**
Subscribed capital	**8.9**	8.9
Capital reserves	**19.8**	19.8
Other reserves	**-4.3**	-5.0
Retained earnings	**-67.1**	-58.1
Equity attributable to owners of the parent	**-42.7**	**-34.4**
Total equity	**-42.7**	**-34.4**
Total equity and liabilities	**76.0**	**57.8**

* preliminary and unaudited

SINGULUS TECHNOLOGIES Group
Income Statement
from January 1 to September 30, 2021 and 2020

	3rd Quarter 2021		3rd Quarter 2020		Jan. 1 - Sept. 30, 2021		Jan. 1 - Sept. 30, 2020	
	[million €]	[%]	[million €]	[%]	[million €]	[%]	[million €]	[%]
Revenue (gross)	**19.5**	**100.0**	5.7	100.0	**45.5**	**100.0**	21.9	100.9
Sales deductions and direct selling costs	**0.0**	**0.0**	0.0	0.0	**0.0**	**0.0**	-0.2	-0.9
Revenue (net)	**19.5**	**100.0**	5.7	100.0	**45.5**	**100.0**	21.7	100.0
Cost of sales	**-13.4**	**-68.7**	-5.3	-93.0	**-32.2**	**-70.8**	-21.9	-100.9
Gross profit on sales	**6.1**	**31.3**	0.4	7.0	**13.3**	**29.2**	-0.2	-0.9
Research and development	**-1.5**	**-7.7**	-2.0	-35.1	**-5.9**	**-13.0**	-6.5	-30.0
Sales and customer service	**-2.1**	**-10.8**	-2.5	-43.9	**-8.2**	**-18.0**	-7.5	-34.6
General administration	**-2.1**	**-10.8**	-2.2	-38.6	**-7.0**	**-15.4**	-6.6	-30.4
Other operating expenses	**-0.1**	**-0.5**	-0.3	-5.3	**-0.1**	**-0.2**	-0.4	-1.8
Other operating income	**0.0**	**0.0**	0.3	5.3	**0.3**	**0.7**	0.6	2.8
Total operating expenses	**-5.8**	**-29.7**	-6.7	-117.5	**-20.9**	**-45.9**	-20.4	-94.0
Operating result (EBIT)	**0.3**	**1.5**	-6.3	-110.5	**-7.6**	**-16.7**	-20.6	-94.9
Finance income	**0.0**	**0.0**	0.0	0.0	**0.0**	**0.0**	0.0	0.0
Finance costs	**-0.6**	**-3.1**	-0.5	-8.8	**-1.5**	**-3.3**	-1.6	-7.4
EBT	**-0.3**	**-1.5**	-6.8	-119.3	**-9.1**	**-20.0**	-22.2	-102.3
Tax expense/income	**-0.1**	**-0.5**	0.4	7.0	**0.1**	**0.2**	0.8	3.7
Profit or loss for the period	**-0.4**	**-2.1**	-6.4	-112.3	**-9.0**	**-19.8**	-21.4	-98.6
Thereof attributable to:								
Owners of the parent	**-0.4**		-6.4		**-9.0**		-21.4	
Non-controlling interests	**0.0**		0.0		**0.0**		0.0	

	[€]	[€]	[€]	[€]
Basic earnings per share based on the profit for the period (in EUR) attributable to owners of the parent	**-0.04**	-0.72	**-1.01**	-2.41
Diluted earnings per share based on the profit for the period (in EUR) attributable to owners of the parent	**-0.04**	-0.72	**-1.01**	-2.41

SINGULUS TECHNOLOGIES Group
Statement of Comprehensive Income

from January 1 to September 30, 2021 and 2020

	3rd Quarter 2021 [million €]	3rd Quarter 2020 [million €]	Jan. 1 - Sept. 30, 2021 [million €]	Jan. 1 - Sept. 30, 2020 [million €]
Profit or loss for the period	**-0.4**	-6.4	**-9.0**	-21.4
Items that will be reclassified to profit and loss:				
Derivative financial instruments	**-0.1**	0.0	**-0.1**	0.0
Exchange differences in the fiscal year	**0.5**	-0.3	**0.8**	-0.2
Total income and expense recognized directly in other comprehensive income	**0.4**	-0.3	**0.7**	-0.2
Total comprehensive income	**0.0**	-6.7	**-8.3**	-21.6
Thereof attributable to:				
Owners of the parent	**0.0**	-8.5	**-8.3**	-14.9

SINGULUS TECHNOLOGIES Group
Statement of Changes in Equity
as of September 30, 2021 and 2020

	Equity Attributable to Owners of the Parent		
	Subscribed Capital	Capital Reserves	Other Reserves*
	[million €]	[million €]	Currency Translation Reserves [million €]
As of January 1, 2020	**8.9**	**19.8**	**3.9**
Profit or loss for the period	0.0	0.0	0.0
Other comprehensive income	**0.0**	**0.0**	**-0.2**
Total comprehensive income	**0.0**	**0.0**	**-0.2**
As of September 30, 2020	**8.9**	**19.8**	**3.7**
As of January 1, 2021*	**8.9**	**19.8**	**3.6**
Profit or loss for the period	0.0	0.0	0.0
Other comprehensive income	**0.0**	**0.0**	**0.8**
Total comprehensive income	**0.0**	**0.0**	**0.8**
As of September 30, 2021	**8.9**	**19.8**	**4.4**

* preliminary and unaudited

Equity Attributable to Owners of the Parent				Equity
Other Reserves*		Retained Earnings*	Total	
Reserves from hedging transactions [million €]	Actual Gains and Losses from Pension Commitments [million €]	Other Retained Reserves [million €]	[million €]	[million €]
0.0	**-7.6**	**-18.0**	**7.0**	**7.0**
0.0	0.0	-21.4	-21.4	-21.4
0.0	**0.0**	**0.0**	**-0.2**	**-0.2**
0.0	**0.0**	**-21.4**	**-21.6**	**-21.6**
0.0	**-7.6**	**-39.4**	**-14.6**	**-14.6**
0.0	**-8.6**	**-58.1**	**-34.4**	**-34.4**
0.0	0.0	-9.0	-9.0	-9.0
-0.1	**0.0**	**0.0**	**0.7**	**0.7**
-0.1	**0.0**	**-9.0**	**-8.3**	**-8.3**
-0.1	**-8.6**	**-67.1**	**-42.7**	**-42.7**

SINGULUS TECHNOLOGIES Group
Statement of Cash Flows
from January 1 to September 30, 2021 and 2020

	Jan. 1 - Sept. 30, 2021 [million €]		Jan. 1 - Sept. 30, 2020 [million €]	
Cash flows from operating activities				
Profit or loss for the period		**-9.0**		-21.4
Adjustment to reconcile profit or loss for the period to net cash flow				
Amortization, depreciation and impairment of non-current assets	**3.0**		3.5	
Contribution to the pension provisions	**0.1**		0.1	
Profit/loss from disposal of non-current assets	**0.0**		0.0	
Other non-cash expenses/income	**-0.4**		-0.2	
Net finance costs	**1.4**		1.6	
Net tax expense	**-0.1**		-0.8	
Change in trade receivables	**0.1**		2.8	
Change in construction contracts	**23.1**		21.6	
Change in other receivables and other assets	**-6.2**		1.5	
Change in inventories	**-4.0**		-0.1	
Change in trade payables	**3.3**		-4.3	
Change in other liabilities	**0.4**		-2.7	
Change in prepayments	**3.2**		1.6	
Change in provisions from restructuring measures	**0.0**		0.0	
Change in further provisions	**-0.4**		0.8	
Interest paid	**-0.1**		-0.4	
		23.4		25.0
Net cash from/used in operating activities		**14.4**		3.6

	Jan. 1 - Sept. 30, 2021 [million €]		Jan. 1 - Sept. 30, 2020 [million €]	
Cash flows from investing activities				
Cash paid for investments in development projects	**-0.2**		-2.1	
Cash paid for investments in other intangible assets and property, plant and equipment	**-0.3**		-0.5	
Net cash from/used in investing activities		**-0.5**		-2.6
Cash flows from financing activities				
Cash used to pay bond interest	**-1.2**		-1.0	
Cash received/used on the issuance of loans	**0.0**		0.0	
Cash used to pay loan interest	**-0.3**		-0.2	
Cash used to pay leasing liabilities	**-1.8**		-1.6	
Cash received/used on financial assets subject to restrictions on disposal	**-7.3**		-0.3	
Net cash from/used in financing activities		**-10.6**		-3.1
Increase/decrease of cash and cash equivalents		**3.3**		-2.1
Effect of exchange rate changes		**0.2**		-0.2
Cash and cash equivalents at the beginning of the reporting period		**9.8**		14.8
Cash and cash equivalents at the end of the reporting period		**13.3**		12.5

Cash and cash equivalents comprise monetary investments with a remaining maturity of up to three months at the time of acquisition.

Financial assets subject to restrictions on disposal are presented separately in the balance sheet. These financial assets relate to the Company's financing transactions and are included in the consolidated cash flow statement as cash flows from financing activities.

Annotations to the interim report

The SINGULUS TECHNOLOGIES Aktiengesellschaft (in the following also "SINGULUS" or the „company") is an exchange-listed capital company domiciled in Germany. The consolidated financial accounts presented for the interim reporting of the SINGULUS TECHNOLOGIES AG and its subsidiaries (the "Group") for the first nine months of the business year 2021 were approved for publication by decision of the Executive Board as of November 5, 2021.

The consolidated financial accounts were drawn up in Euro (€). If not stated otherwise, all figures are in millions of Euro (million €). Due to statements in million € differences in rounding may occur.

Accounting and valuation principles
The preparation of the abbreviated consolidated interim results for the period from January 1 to September 30, 2021 was made pursuant to IAS 34 "Interim Financial Reporting". The interim financial accounts were neither audited nor reviewed by auditors. Furthermore, we would like to point out that the annual and consolidated financial statements for the 2020 financial year and thus the opening balance sheet figures for the current reporting period have yet to be audited by the responsible auditor.

At the beginning of the year, the issuing of the attestation was largely dependent, among other things, on the successful refinancing or the extension of the outstanding, interest-bearing liabilities and thus also on the successful resolution on the new bond conditions on May 6, 2021.

The resolutions to amend the bond in July 2021 have now been implemented with legal effect.

In order to secure the continued existence of the company, the provision of an additional, unsecured working capital credit line of up to € 10.0 million is required. For this purpose, the Company is in contact with Chinese commercial banks with the support of the Chinese main shareholder CNBM. Likewise, a successful refinancing of the still outstanding senior secured loan in the amount of € 4.0 million is to be achieved. The Executive Board expects a positive conclusion of the talks with the financing partners in the course of the fourth quarter of 2021. Furthermore, order intake is still required for the next few weeks. The advance payments for the contracts signed on October 29, 2021 must be received as planned. If these targets are met, the Executive Board expects the audit certificate to be issued in the course of the fourth quarter of 2021.

The consumption of more than half of the nominal capital pursuant to HGB was incurred in the business year 2017 and was reported on September 21, 2017. The extraordinary shareholders' meeting was convened on November 29, 2017. In the course of the extraordinary general meeting on October 29, 2021, pursuant to Art. 92 Para. 1 AktG the Executive Board again reported on the loss of the nominal capital pursuant to HGB of the parent company. The background to the depletion of shareholders' equity was presented, which was mainly due to the postponement of revenue recognition in HGB and IFRS and the operating losses resulting from the underutilization of the organization in recent years.

The preliminary financial figures for the first nine months of the 2021 financial year were explained to the Extraordinary General Meeting However, from today's point of view, the company has sufficient available liquid funds to safeguard the course of business and therefore draws up the financial statement according to the going-concern assumptions.

These events and circumstances indicate that there are material uncertainties which can raise doubts as to the ability of the Company to continue to operate as a going concern within the meaning of § 322 (2) sentence 3 HGB.

The preparation of the interim results pursuant to IAS 34 requires estimates and assumptions by the management, affecting the level of the reported assets, liabilities, sales, income, expenses as well as contingent liabilities. These assumptions and estimates mainly affect the Group-consistent determination of useful life expectancy, the write-offs of assets, the valuation of provisions, the recoverability of receivables, the determination of realizable terminal values with regards to inventories as well as the realizability of future tax relieves. The actual values can differ from the assumptions and estimates made on a case by case basis. Any changes are recognized as profit and loss at the time of the knowledge gained. The accounting and valuation methods applied for the consolidated accounts for the interim reporting correspond to those applied for the most recent published consolidated financial report as of the end of the business year 2019. For a detailed description of the accounting principles please refer to the notes of the consolidated financial statements of our Annual Report 2019.

Scope of consolidation

In addition to the SINGULUS TECHNOLOGIES AG, the consolidated financial statements include all companies, which are legally or factually controlled by the company. In the interim report as of September 30, 2021, in addition to the SINGULUS TECHNOLOGIES AG in total two domestic and nine foreign subsidiaries were included. No companies have been added or excluded from the scope of consolidation in the period under review.

Accounts receivable and receivables from production orders

The accounts receivable and production receivables as of September 30, 2021 are split as follows:

	Sept. 30, 2021 in million €	Dec. 31, 2020 in million €
Accounts receivable – short-term	**3.1**	**3.3**
Receivables from production orders	**2.7**	**3.1**
Less allowances	**-0.1**	**-0.1**
	5.7	**6.3**

Intangible assets

Capitalized development expenses, goodwill, customer bases as well as concessions, intellectual property rights and other intangibles are included under intangible assets. As of September 30, 2021, the capitalized development expenses amounted to € 4.2 million (December 31, 2020: € 5.2 million). In the first nine months of 2021 the investments in developments totaled € 0.2 million (previous year: € 2.1 million). Scheduled write-offs and amortization on capitalized development expenses amounted to € 1.1 million (previous year: € 1.3 million). In the quarter under review development expenses amounted to € 0.0 million (previous year: € 0.6 million), the scheduled amortization amounted to € 0.2 million (previous year: € 0.4 million).

Property, plant & equipment

In the first nine months of the business year 2021 € 0.3 million were invested in property, plant & equipment (previous year: € 0.5 million). During the same period scheduled depreciation amounted to € 1.9 million (previous year: € 2.1 million). The scheduled depreciation for the quarter under review amounted to € 0.6 million (previous year: € 0.7 million).

Breakdown of sales

The following matrix splits sales in the period under review according to the individual segments and selected categories.

January 1 to September 30, 2021	Solar in million €	Life Science in million €	Semiconductor in million €	Total in million €
Sales by country of destination				
Germany	4.5	0.8	3.7	9.0
Rest of Europe	0.4	4.7	0.5	5.6
North and South America	0.0	4.5	0.4	4.9
Asia	20.1	5.3	0.5	25.9
Africa & Australia	0.0	0.1	0.0	0.1
	25.0	**15.4**	**5.1**	**45.5**
Sales by country of origin				
Germany	24.6	10.1	4.2	38.9
Rest of Europe	0.0	0.3	0.1	0.4
North and South America	0.0	3.8	0.4	4.2
Asia	0.4	1.2	0,4	2.0
Africa & Australia	0.0	0.0	0.0	0.0
	25.0	**15.4**	**5.1**	**45.5**
Products and services				
Production facilities	23.4	8.2	4.2	35.8
Service and spare parts	1.6	7.2	0.9	9.7
	25.0	**15.4**	**5.1**	**45.5**
Revenue recognition date				
Periodic revenue recognition	22.3	8.3	4.1	34.7
Revenue recognition as of a specific date	2.5	7.2	1.1	10.8
	25.0	**15.4**	**5.1**	**45.5**

January 1 to September 30, 2020	Solar in million €	Life Science in million €	Semiconductor in million €	Total in million €
Sales by country of destination				
Germany	3.6	0.5	0.8	4.9
Rest of Europe	0.2	5.0	0.2	5.4
North and South America	0.4	3.8	0.4	4.6
Asia	4.0	1.6	1.3	6.9
Africa & Australia	0.0	0.1	0.0	0.1
	8.2	**11.0**	**2.7**	**21.9**
Sales by country of origin				
Germany	7.5	5.8	1.8	15.1
Rest of Europe	0.0	0.2	0.1	0.3
North and South America	0.3	3.3	0.7	4.3
Asia	0.4	1.7	0.1	2.2
Africa & Australia	0.0	0.0	0.0	0.0
	8.2	**11.0**	**2.7**	**21.9**
Products and services				
Production facilities	6.5	3.8	2.0	12.3
Service and spare parts	1.7	7.2	0.7	9.6
	8.2	**11.0**	**2.7**	**21.9**
Revenue recognition date				
Periodic revenue recognition	6.5	3.7	1.7	11.9
Revenue recognition as of a specific date	1.7	7.3	1.0	10.0
	8.2	**11.0**	**2.7**	**21.9**

Sales deductions and direct selling costs
The sales reductions include all cash discounts granted. The individual selling expenses are mainly composed of expenses for packaging, freight and commissions.

General administrative expenses
Administrative expenses include management expenses, HR expenses and finance and accounting expenses as well as the premises and vehicle expenses attributable to such areas. Furthermore, they include the ongoing IT expenses, legal and consulting fees, expenses for investor relations activities, the ordinary Annual General Meeting as well as the annual financial statements.

Research and development expenses
In addition to the research expenses and non-capitalizable development expenses, the research and development expenses in the first nine months of 2021 still include the scheduled amortization of capitalized development efforts in the amount of € 1.1 million (previous year: € 1.3 million). During the third quarter of 2021 write-offs on capitalized development activities amounted to € 0.2 million (previous year: € 0.4 million).

Financial instruments
The following table shows the carrying amounts and fair values of all financial instruments recognized in the consolidated financial statements by category.

		Carrying amount		Fair values	
	Measurement method	Sept. 30, 2021 in million €	Dec. 31, 2020 in million €	Sept. 30, 2021 in million €	Dec. 31, 2020 in million €
Financial assets					
Cash and cash equivalents **	AC	13.3	9.8	13.3	9.8
Financial assets subject to restrictions on disposal **	AC	12.1	4.8	12.1	4.8
Derivatives					
Hedging Derivatives **	HD	–	–	–	–
Trade receivables **	AC	3.1	3.2	3.1	3.2
Other receivables	AC	10.3	3.8	10.3	3.8
Financial liabilities					
Bond *	AC	12.1	12.7	9.6	12.5
Liabilities from loans	AC	4.0	4.0	4.0	4.0
Derivatives					
Hedging Derivative **	HD	0.1	0.0	0.1	0.0
Trades payables **	AC	9.7	6.5	9.7	6.5
Other liabilities	AC	6.8	7.1	6.8	7.1
Total	AC	71.4	52.0	68.9	51.7
Total	HD	0.1	0.0	0.1	0.0

* The valuation at attributable time value was accounted for as Level 1 attributable time value, based on the input factors of the applied valuation procedures.
** The valuations at attributable time value were accounted for as Level 2 attributable time values, based on the input factors of the applied valuation procedures.

Abbreviations:
AC: Financial assets and liabilities measured at amortized cost
HD: Hedging Derivative

Cash and cash equivalents, financial assets subject to restrictions on disposal, and trade payables are generally due in the short term. The balance sheet values are approximately the attributable time values. The same holds true for short-term accounts receivables and other assets.

The attributable time values of long-term accounts receivable corresponds to the present values corresponding to the payments of the assets subject to the relevant interest rate parameters.

Forward exchange contracts are measured using the ECB reference rates for spot currency and the valid forward exchange rates of the respective commercial bank for forward currency.

The fair value of the exchange-listed bond equals the market price as of the balance sheet date plus the carrying amount of accrued interest liabilities as of the balance sheet date.

The attributable time value of the liabilities from the issuance of loans corresponds to the redemption amount of the loans at the balance sheet date.

The maximum credit risk is reflected in the carrying amounts of the financial assets and liabilities.

Financial income and financing expenses

The interest income/ expenses are composed as follows:

	Sept. 30,2021 in million €	Sept. 30,2020 in million €
Financing expenses from issuance of bond	-0.6	-0.6
Interest expenses from the discounting of pension provisions	-0.2	-0.2
Interest expenses from capitalized leasing contracts	-0.4	-0.4
Other finance expenses	-0.3	-0.4
	-1.5	-1.6

Earnings per share

For the calculation of the undiluted earnings per share the earnings attributable to the bearers of the common shares of the parent company are divided by the weighted average number of shares in circulation during the period under review.

For the calculation of the diluted earnings per share the earnings attributable to the bearers of the common shares of the parent company are divided by the weighted average number of common shares in circulation during the period under review in addition to the weighted average number of shares resulting from the conversion of all potential common shares with dilution effect into common shares. Dilution effects were neither recorded in the quarter under review nor in the same period one year ago. In the period from the balance sheet date until the drawing up of the consolidated financial statements there were no transactions of common shares or potential common shares.

Financing liabilities from bond issue
The security bond (ISIN DE000A2AA5H5) with a volume of € 12.0 million was issued in July 2016. The original term of five years was extended by five additional years as per resolution on May 6, 2021. The interest rate for the last year of the original term to maturity amounts to 10.0 % p.a.. The effective interest rate for the first five years amount to 6.7 % p.a..

The nominal interest rate for the extended term to maturity amounts to 4.5 % p.a.. The redemption amount per corporate bond with a nominal amount of EUR 100.00 shall be increased by € 5.00 to € 105.00. The effective interest rate for the additional five years amount to 5.4 % p.a..

Cash, receivables, inventories, fixed assets and intangible assets of the SINGULUS TECHNOLOGIES AG serve primarily as collateral for the bond.

Liabilities from loans
In February 2019 the company has taken a loan in the amount of € 4.0 million from a bondholder. The original term of the loans was one year. In March 2020, the term to maturity was extended to March 2021. Currently, the Executive Board is negotiating a further extension of the financing. The loan is in context of the bond provisions Art. 8 (a) (iv) in connection with Art. 3 (e). Accordingly, the company is able to enter financial liabilities in form of a loan of up to € 4.0 million. In this context, the bond collateral was also used for securing the loan. This was senior ranking compared with the bondholders. The effective interest rate amounts to 9.97 % per year.

Events after the Balance Sheet Date
On October 29, 2021, the company signed delivery contracts for production machines for the manufacturing of CdTe and CIGS solar modules in the amount of approximately € 25 million with the major Chinese customer and shareholder Triumph Science and Technology Group Co, Ltd. (a 100 % subsidiary of the CNBM Group).

There were no other material events after the balance sheet date.

Shareholdings of Board members
As of the balance sheet date, the members of the Executive and Supervisory Boards of the SINGULUS TECHNOLOGIES AG held the following number of shares, convertible bonds and stock options: As of September 30, 2021 the Chairman of the Supervisory Board, Dr.-Ing. Leichnitz, held 245 shares of the company overall, the Supervisory Board member Ms. Silke Landwehrmann held 2,000 shares of the company as of September 30, 2021.

Furthermore, at the end of the quarter under review members of the Executive Board had themselves purchased the following number of shares of the SINGULUS TECHNOLOGIES AG:

	Sept. 30, 2021 shares
Dr.-Ing. Stefan Rinck, CEO	122
Markus Ehret, CFO	43
Dr. rer. nat. Christian Strahberger, COO	2,000
	2,165

Affirmation of the Legal Representatives

“We assert to our best knowledge and belief that pursuant to the applicable accounting principles for the interim financial reporting the consolidated financial statements reflect the true situation of the asset, financial and earnings situation of the Group. The consolidated interim status report depicts the course of business including the financial results and the situation of the Group in a way reflecting the true situation and describing the material opportunities and risks of the foreseeable developments of the Group during the remainder of the business year.”

Kahl am Main, November 2021

The Executive Board

Financial Key Figures for the Third Quarter

(preliminary and unaudited)

		2020	2021
Revenue (gross)	million €	5.7	19.5
Order intake	million €	4.0	37.0
EBIT	million €	-6.7	0.3
EBITDA	million €	-5.1	0.9
Earnings before taxes	million €	-6.8	-0.3
Profit/loss for the period	million €	-6.4	-0.4
Research & development expenditures	million €	2.5	2.2

Financial Key Figures for the First 9 Months

(preliminary and unaudited)

		2020	2021
Revenue (gross)	million €	21.9	45.5
Order intake	million €	70.9	73.3
Order backlog (09/30)	million €	75.3	105.6
EBIT	million €	-20.6	-7.6
EBITDA	million €	-17.1	-4.7
Earnings before taxes	million €	-22.2	-9.1
Profit/loss for the period	million €	-21.4	-9.0
Operating cash flow	million €	3.6	14.4
Shareholders' equity	million €	-14.6	-42.7
Balance sheet total	million €	75.7	76.0
Research & development expenditures	million €	8.1	7.2
Employees (09/30)		355	338
Weighted number of shares, basic		8,896,527	8,896,527
Earnings per share, basic	€	-2.41	-1.01

Future-oriented Statements and Forecasts

This report contains future-oriented statements based on the current expectations, assessments and forecasts of the Executive Board as well as on the currently available information to them. Known as well as unknown risks, uncertainties and impacts could cause the actual results, the financial situation or the development to differ from the statements made in this report. We assume no obligation to update the futureoriented statements made in this report.

SINGULUS TECHNOLOGIES AG
Hanauer Landstrasse 103
D-63796 Kahl am Main
Tel. +49 6188 440-0
Fax +49 6188 440-1110
Internet: www.singulus.de

Investor Relations
Maren Schuster
Tel. +49 6188 440-1612
Fax +49 6188 440-1110
investor.relations@singulus.de

Studio Krause – 11/2021